Drugs / Envarsus
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Envarsus | — | 2014-07-18 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03241043 | May 2016 → Apr 2019 | — | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT03555448 Comparator | Jun 2018 → Nov 2023 | — | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT04973982 Comparator | Jan → Aug 2022 | — | Barts & The London NHS Trust | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Envarsus | “Once daily medication regimen (Envarsus and azathioprine)” NCT03555448 ↗ |
| Known as | tacrolimus | “switching from the current standard of care twice daily Adoport (Tacrolimus) to once daily Envarsus (tacrolimus)” NCT04973982 ↗ |
| Route | Oral | “3 month treatment, given once daily, oral tablet” NCT04973982 ↗ |